|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
mood stabilizer
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N03AG01
|
|
gptkbp:brand
|
gptkb:Depakene
gptkb:Depakote
gptkb:Epilim
|
|
gptkbp:CASNumber
|
99-66-1
|
|
gptkbp:cause
|
gptkb:encephalopathy
gptkb:polycystic_ovary_syndrome
birth defects
nausea
vomiting
dizziness
liver failure
alopecia
pancreatitis
rash
drowsiness
ataxia
thrombocytopenia
hyperammonemia
menstrual irregularities
|
|
gptkbp:chemicalFormula
|
C8H16O2
|
|
gptkbp:contraindication
|
gptkb:liver_disease
pregnancy
|
|
gptkbp:discoveredBy
|
gptkb:Pierre_Eymard
|
|
gptkbp:discoveredIn
|
1962
|
|
gptkbp:eliminationHalfLife
|
9–16 hours
|
|
gptkbp:heldBy
|
gptkb:carboxylic_acid
branched-chain fatty acid
teratogen
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Valproic acid
|
|
gptkbp:isOn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:IUPACName
|
gptkb:2-propylpentanoic_acid
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks voltage-gated sodium channels
increases GABA levels
inhibits T-type calcium channels
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
144.21 g/mol
|
|
gptkbp:pregnancyCategory
|
D
|
|
gptkbp:PubChem_CID
|
3121
DB00313
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
tremor
hair loss
weight gain
hepatotoxicity
teratogenicity
|
|
gptkbp:UNII
|
614OI1Z5WI
|
|
gptkbp:usedFor
|
bipolar disorder
epilepsy
migraine prophylaxis
|
|
gptkbp:bfsParent
|
gptkb:Anticonvulsants
|
|
gptkbp:bfsLayer
|
7
|